DDInter223 DDInter899
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Bosentan {u} (Compound) binds {v} (Gene) EDNRA
Bosentan {u} (Compound) downregulates {v} (Gene) PSMB8
Bosentan {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Bosentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Bosentan {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Bosentan (Compound) binds EDNRA (Gene)
Bosentan (Compound) downregulates PSMB8 (Gene)
Bosentan (Compound) causes Hepatobiliary disease (Side Effect)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Bosentan may lead to a major life threatening interaction when taken with Encorafenib